Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, Bander NH, Schoder H, Bodei L, Pandit-Taskar N, Lewis JS, Larson SM, Osborne JR, Pillarsetty NVK. Kalidindi TM, et al. Among authors: bodei l. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2642-2651. doi: 10.1007/s00259-020-05150-w. Epub 2021 Jan 25. Eur J Nucl Med Mol Imaging. 2021. PMID: 33495926 Free PMC article.
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Cwikla J, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169. doi: 10.1007/s00259-018-3967-6. Epub 2018 Feb 26. Eur J Nucl Med Mol Imaging. 2018. PMID: 29484451 Free PMC article.
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.
Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Cremonesi M, et al. Among authors: bodei l. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. doi: 10.1007/s00259-018-4044-x. Epub 2018 May 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785514 Free PMC article. Review.
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.
Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA. Reidy-Lagunes D, et al. Among authors: bodei l. Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439583 Free PMC article. Clinical Trial.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Kratochwil C, et al. Among authors: bodei l. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31440799
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Prasad V, Srirajaskanthan R, Toumpanakis C, Grana CM, Baldari S, Shah T, Lamarca A, Courbon F, Scheidhauer K, Baudin E, Truong Thanh XM, Houchard A, Dromain C, Bodei L. Prasad V, et al. Among authors: bodei l. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2358-2371. doi: 10.1007/s00259-020-04712-2. Epub 2020 Feb 15. Eur J Nucl Med Mol Imaging. 2020. PMID: 32062681 Free PMC article.
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.
Krebs S, O'Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, Pandit-Taskar N. Krebs S, et al. Among authors: bodei l. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. doi: 10.1007/s00259-020-04832-9. Epub 2020 May 6. Eur J Nucl Med Mol Imaging. 2020. PMID: 32378020 Free PMC article. Clinical Trial.
216 results